Resurrection of extinct species
Recovering an extinct animal's genome from preserved remains, writing it into the cells of a living relative, and gestating living animals of the lost species.
In shortResurrection of extinct species, from Jurassic Park (Michael Crichton, 1990) and Blindsight (Peter Watts, 2006), is at technology readiness level 3 of 9 (experimental proof of concept) at its weakest link. Held back by Reconstructed implantation and placentation. Science status: underlying science well understood; an engineering problem. Estimated new funding to unlock: $3.1B–13B.
InGen recovers dinosaur DNA from biting insects preserved in amber, patches the gaps with reptile and amphibian sequence, and incubates the embryos in artificial eggs to stock an island park.
Vampires, a Pleistocene human subspecies, are resurrected from recovered DNA; Jukka Sarasti commands the Theseus.
Closest todayColossal reconstructed about 91 percent of the dire wolf genome, made 20 edits at 14 loci in gray wolf cells and produced two live pups from 45 embryos in 2025 - phenotypic approximations, not restored species; DNA decay makes Mesozoic genomes unrecoverable in principle.
Dependency stack
- criticalAncient genome reconstructionYou cannot rebuild a genome you cannot read, and amber-preserved DNA from the Mesozoic does not exist to be read
✕4 blockers›
- Endogenous DNA does not survive beyond roughly 1-1.5 million years, so pre-Pleistocene genomes are unrecoverable in principle
- Short, damaged fragments cannot be phased, so haplotypes and structural variation are lost
- Regulatory and non-coding sequence - much of what makes a phenotype - is the least recoverable part
- A reference-guided assembly inherits the living relative's genome where coverage is missing, so the reconstruction is partly circular
TRL 4 - An edited cell line becomes an animal only through nuclear transfer, at a few percent efficiency
✕3 blockers›
- Incomplete epigenetic reprogramming of the donor nucleus produces placental defects and large-offspring syndrome
- Efficiency is a few percent of transferred embryos, so each live birth consumes many donor eggs and surrogates
- Donor egg supply is the limiting input for any primate-scale program
TRL 5 - criticalMultiplex genome engineeringConverting a relative's genome toward the extinct one means tens to thousands of simultaneous edits
✕3 blockers›
- Structural variants and large deletions accumulate with edit count and are missed by short-read screening
- Edited cell lines lose clonogenic and developmental potency after many rounds of editing
- No method reaches the thousands of edits implied by whole-genome rewriting
TRL 6- Higher-fidelity, smaller editor and recombinase proteins are the route to many simultaneous edits
✕1 blocker›
- Designing catalysis and conformational dynamics
TRL 6
- No conspecific female exists, so a related species must carry the pregnancy
✕4 blockers›
- Placental and immunological incompatibility between embryo and surrogate species causes early loss
- Success rates of a few percent mean each live birth consumes many embryos and surrogate cycles
- Oocyte supply for enucleation depends on the surrogate species, which constrains how distant the target species can be
- Maternal behavior, microbiome and milk of the wrong species shape the offspring after birth
TRL 4- Failures occur at implantation and placentation, which is where the biology is unknown
- The placenta's endocrine and nutrient-exchange functions have not been reproduced by any device or culture
- Maternal immune tolerance at the interface is not understood well enough to substitute for
- Human implantation cannot be studied past the 14-day limit, so the critical window is inaccessible
TRL 3 - The embryo to be transferred is produced by nuclear transfer into a surrogate-species eggTRL 5
- supportingFull-term ectogenesisThe novel's artificial eggs bypass surrogates entirely, which no program can currently do
✕3 blockers›
- The gap between day-14 embryo culture and artificial-placenta viability covers organogenesis, the hardest and least substitutable phase
- No artificial implantation or placental organ exists to supply hormones and nutrient exchange during that gap
- Scaling implies thousands of parallel units with sterility and uninterrupted power for nine months each
TRL 2- The early half cannot be built without reconstructing implantation and placental exchangeTRL 3
- An engineered placenta is a vascularized tissue that must be grown, not just machined
✕4 blockers›
- Capillary-scale perfusion cannot be printed and must self-assemble, which is uncontrolled today
- Printed tissue must mature into function (filtration, metabolism, contraction), and maturation protocols stall at fetal-like performance
- Cell demand of 10^10-10^11 per organ exceeds current manufacturing
- Mechanical integration - ureters, bile ducts, valves - has no demonstrated fabrication route
TRL 4- Without a capillary network, tissue thicker than a few hundred microns dies
✕3 blockers›
- Printing resolution stops at tens of microns while capillaries are 5-10 microns, so the smallest and most numerous vessels must self-assemble
- Engineered endothelium is thrombogenic, so perfused constructs clot
- No method guides anastomosis of a construct's vasculature to host vessels at scale
TRL 3 - Banked-cell organs are not patient-matched, so acceptance must be engineered
✕3 blockers›
- Chronic antibody-mediated rejection proceeds even under current immunosuppression
- Tolerance protocols trade rejection risk for conditioning toxicity and graft-versus-host disease
- No assay predicts which recipients can be safely weaned off drugs
TRL 5 - One organ needs 10^10-10^11 clinical-grade cells of several types
✕3 blockers›
- Genomic instability and drift accumulate over the expansion needed for 10^11 cells
- Each organ needs many cell types differentiated on a synchronized schedule, not one lineage
- Cost per cell at current media and reagent prices makes a printed organ unaffordable
TRL 6
- Supplies the late-gestation half of the problem
✕4 blockers›
- Miniaturization - the lamb model weighs 1-3 kg while a 23-week human fetus is about 500 g, with shorter umbilical cannulation distances
- Umbilical vessel vasospasm and thrombosis during cannulation and over weeks of support
- Infection control in a continuously exchanged sterile fluid environment
- No agreed proof-of-concept endpoint or animal model that maps onto human neonatal outcomes
TRL 5- Sterile fluid exchange, nutrition and waste handling must run continuously without interruption
✕2 blockers›
- Food production closure
- Microbial and ecological stability over years
TRL 5 - Gas exchange through the umbilical circuit for weeks is the core function
✕3 blockers›
- Blood-surface contact activates coagulation, so runs depend on anticoagulation that causes bleeding in fragile patients
- Oxygenator plasma leakage and fiber fouling limit single-circuit life
- Hemolysis and platelet consumption scale with pump shear and circuit length
TRL 7
Who could unlock it
- Across several requirements:
- Colossal Biosciences 4
- Avantea 2
- Jacob HannaResearcher, Weizmann Institute of ScienceBuilt the ex utero mouse embryo culture platform (Nature, 2021) that the 2026 extension into the fetal period is based on
- Nicolas RivronResearcher, Institute of Molecular Biotechnology, Austrian Academy of SciencesMakes human blastoids that attach to hormonally primed endometrial organoids, and used the assay to screen compounds that block implantation
- Ashley MoffettResearcher, University of CambridgeShowed uterine natural killer cells control extravillous trophoblast differentiation in early pregnancy (Cell Stem Cell, 2024), the core of maternal immune tolerance
- Centre for Trophoblast ResearchAcademic labCambridge centre supplying the trophoblast organoid and placental-interface biology the rest of the field builds on
- Colossal BiosciencesStartupAssembled two dire wolf genomes from Pleistocene remains and used them to select 20 edits at 14 loci (2025); has raised over $435M since 2021
- Beth ShapiroResearcher, Colossal Biosciences (on leave from UC Santa Cruz)Chief science officer who led the dire wolf paleogenome reconstruction and the 2025 methods paper on assembling degraded ancient genomes
- Love DalenResearcher, Centre for Palaeogenetics, Stockholm UniversityLed the consortium that recovered million-year-old mammoth genomes (2021) and the oldest sequenced RNA, from a 40,000-year-old mammoth (Cell, 2025)
- Max Planck Institute for Evolutionary AnthropologyAcademic labSvante Paeaebo's institute produced the Neanderthal and Denisovan genomes and the ancient-DNA library and contamination methods the field still uses
- BioRescueProgramGerman-funded consortium that had conducted six northern white rhino embryo transfers into southern white rhino surrogates as of April 2026, none yielding a lasting pregnancy
- Thomas HildebrandtResearcher, Leibniz Institute for Zoo and Wildlife ResearchHeads BioRescue and performs the rhino transfers; received the inaugural Smart Wildlife Conservation Award in January 2026
- Colossal BiosciencesStartupGestated edited gray-wolf embryos in domestic dog surrogates (announced 2025) and in April 2026 announced a bluebuck programme that will use roan antelope surrogates
- AvanteaCompanyCesare Galli's Italian laboratory, which produces the northern white rhino IVF embryos and derived the first southern white rhino embryonic stem cells in 2018
- Qiang SunResearcher, Institute of Neuroscience, Chinese Academy of SciencesCloned the macaques Zhong Zhong and Hua Hua (2018) and ReTro, the first cloned rhesus to reach adulthood, using trophoblast replacement (2024)
- Institute of Neuroscience, Chinese Academy of SciencesGovernment labThe only group to have produced primate clones; its 2024 result consumed 113 transferred embryos for one surviving animal
- ViaGen Pets and EquineCompanyThe commercial SCNT operation, cloning cats, dogs and horses and the Przewalski's horse Kurt; acquired by Colossal Biosciences in November 2025
- Colossal BiosciencesStartupUses cloning from edited cell lines as its route to live animals and bought ViaGen in 2025 to bring that throughput in-house
- eGenesisStartupIts 69-edit Yucatan miniature pigs supply clinical xenotransplants; a kidney from one functioned 271 days in a patient, reported September 2026
- Colossal BiosciencesStartupMade eight simultaneous edits across seven genes in its woolly mouse (March 2025) and 20 edits at 14 loci in a gray wolf cell line
- George ChurchResearcher, Harvard Medical School and Wyss InstituteOriginated multiplex genome engineering and co-founded both eGenesis and Colossal; the 2025 woolly mouse work used his lab's multiplexing toolset
- RevivicorCompanyUnited Therapeutics subsidiary whose 10-edit pigs produced the first gene-edited pig heart transplants and now supply FDA-cleared xenotransplant trials
Beyond engineering
- A phenotypic approximation is not a species, so conservation value and claims are contested
- Release and containment of engineered animals falls between wildlife and biotech regulation
- Animal welfare cost of low-efficiency cloning and surrogate pregnancies